Sectors
Foley & Lardner LLP partner Louis Lehot shared insights on the factors fueling the biotech IPO rebound in the Mergermarket article, “Biotech IPO window widens as M&A fuels 2026 revival.”
Lehot noted that large pharmaceutical companies facing patent expirations are increasingly turning to acquisitions to replenish their pipelines.
“Once a drug demonstrates commercial potential, larger drugmakers can provide the sales and marketing infrastructure needed to scale the product and may ultimately acquire the developer, either before or after an IPO,” he said.
